Application of PTGDS inhibitor in preparation of drug for treating cataracts
US12220411B1 · kind B1 · utility
0Cited by
0References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 8, 2023 |
| Grant date | Feb 11, 2025 |
| Priority date | — |
| Expiry date | Oct 8, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P27/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Application of a PTGDS inhibitor in preparation of a drug for treating cataracts is provided. As an effective and selective PTGDS inhibitor, AT-56 competitively inhibits production of PGD2 by occupying a catalytic site of PTGDS. The PTGDS catalyzes synthesis of the PGD2 to cause an oxidative stress injury of human lens epithelial cells, thereby promoting occurrence and development of aging and opacity of a lens. By reducing apoptosis caused by the oxidative stress injury, a degree of the cataracts can be effectively reduced.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.